Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLA: Osimertinib Induction and Maintenance with Radiotherapy in Unresectable Stage III EGFR-mutant NSCLC
ChiCTR2600124132Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Progression-Free Survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600124132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124132.